Stock SGMT SAGIMET BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-05-14 pm EDT 		5-day change 1st Jan Change
4.62 USD +5.48% Intraday chart for Sagimet Biosciences Inc. +4.05% -14.76%
May. 15 Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 06 Sagimet Biosciences Names Thierry Chauche CFO MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GL
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
AQ
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
GL
Sagimet Biosciences Names Thierry Chauche CFO
MT
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
GL
Sagimet Biosciences Inc. Announces Appointment of Thierry Chauche as Chief Financial Officer
CI
HC Wainwright Starts Sagimet Biosciences With Buy Rating, $32 Price Target
MT
Certain Warrants of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
CI
Certain Options of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
CI
Certain Series A Common Stock of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
CI
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
GL
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
GL
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
AQ
Sagimet Biosciences Inc. Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
CI
Goldman Sachs Adjusts Sagimet Biosciences' Price Target to $27 From $37, Maintains Buy Rating
MT
Leerink Partners Initiates Sagimet Biosciences With Outperform Rating, $26 Price Target
MT
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
GL
Sagimet Biosciences Inc. Announces Management Changes
CI
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGMT Stock
  4. News Sagimet Biosciences Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW